Jacada’s Customer Service RPA two-time winner of the UK National Innovation Award
Award recognizes Jacada’s unique, hybrid approach to robot and human intelligent automation with its Smart Agent Assistant
ATLANTA, May 02, 2019 (GLOBE NEWSWIRE) -- Jacada, Inc., provider of Autonomous CX solutions designed to automate customer service operations, and improve the customer experience, announced that it has been selected as the winner in the Automating Customer Support category of the 2019 UK National Innovation Awards for its Smart Agent Assistant solution for contact centers. This cutting-edge virtual assistant for agents rounds out Jacada’s Intelligent Agent Engagement portfolio and strengthens their leadership position in the Customer Service Automation space.
The Smart Agent Assistant takes a digital approach to solving a legacy problem that has plagued contact centers for years -- agents struggling to provide exemplary customer service despite having to work with a disparate and complex desktop environment. With over 29 years of contact center IP and implementation experience, Jacada is a pioneer in this new digital approach. Decades of experience culminates with human and robot collaboration combining leading-edge technologies like best in class Attended RPA (Robotic Process Automation) and real time guidance with industry leading AI to deliver a one of a kind virtual assistant for contact center agents.
“Bringing cognitive solutions to front line agents represents a long overdue paradigm shift that is changing the way our enterprise clients interact with their customers,” explains Scott Merritt, VP Global Head of Automation, “We are truly excited to see the early interest and adoption of this innovation and are honored to be recognized by the Directors’ Club for this award.”
Jon Snow, founder and chairman of Directors’ Club added, “Automating customer support to meet customers’ 24/7, digital-first expectations and reduce contact centre volumes, has become strategically important for organisations across the business verticals. Jacada’s innovation proved a winner with the judges, making them a two-times UK National Innovation Award winner. Many congratulations. I look forward to sharing your innovation via the Winner’s Webinar.”
The Winner’s Webinar will be held Thursday, June 6, 2019 at 13:00 GMT, 8:00 AM EST.
Register today on the Directors’ Club website here.
The judges for the UK National Innovation Awards were recruited from the Directors’ Club membership. Each judge is a customer, operations or digital-centric leader from end-user organizations. 110 Directors’ Club members judged the finals, with over 60 members judging each category.
Jacada’s automation expertise and IP within customer operations continues to deliver end-to-end customer service automation solutions to global enterprises helping them move further down an autonomous CX path. From guiding the contact center agents and automating their manual tasks to fully automated self-service solutions, Jacada automates interactions while improving customer experience. Our 29 years of experience in automating customer service processes for global enterprises, together with proven outcome-focused integration capabilities, enable worry-free deployments with lower Total Cost of Ownership. Founded in 1990, Jacada operates globally with offices in Atlanta, USA; London, England; Munich, Germany; and Herzliya, Israel. More information is available at www.Jacada.com.
About the UK National Innovation Awards
The UK National Innovation Awards (the Nationals) have been designed by the Directors’ Club United Kingdom to recognize business technology innovations and their impact on customer experience, employee engagement, operations performance, product creation, and profitable growth.
Sr. Product Marketing Manager
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Gainsight Unveils the Customer Cloud, the Future of Customer Success Technology23.5.2019 19:30:00 CEST | Pressemelding
New Products Announced at Pulse 2019 to Drive Customer Success Across the Enterprise SAN FRANCISCO, May 23, 2019 (GLOBE NEWSWIRE) -- Today, Gainsight® launched the Customer Cloud —a first-of-its-kind solution for subscription businesses looking to adopt a customer-centric philosophy that enables them to retain customers while also driving company growth post-sale. According to the 2018 Subscription Economy Index report, subscription companies are growing five times faster than S&P and retail sales. The Gainsight Customer Cloud caters to these businesses by combining the company’s Customer Success and Product Experience products with three new product innovations to offer a powerful set of solutions for businesses to optimize their subscription strategies through technology. “With the maturity of cloud technology and the subscription economy, customer expectations have drastically changed. Companies are struggling to leverage existing tools to satisfy the increasing demands of their cus
Lowered Return Expectations Among Several Trends Pointing to a Shift in Private Markets Due Diligence says New eVestment Survey23.5.2019 15:30:00 CEST | Pressemelding
ATLANTA, May 23, 2019 (GLOBE NEWSWIRE) -- Private markets funds have continued to rake in new commitments from institutional investors eager to diversify their portfolios and capture the returns private markets investments can offer. However, investors are now tempering their private markets return expectations. Coupled with other industry trends, this will have implications for private markets fundraising and due diligence according to a new eVestment report, produced in association with parent company Nasdaq. The 2019 eVestment Private Markets Due Diligence Survey of institutional investors, consultants and private markets fund managers finds that 52% of investors expect returns in the space to decline in the future (page 16). Only 12% of investors expected private equity returns to increase, with the balance – 36% – expecting returns to stay about the same. Forty-seven percent of investors surveyed expect to see lower returns in venture capital vs. just 16% of investors who expect r
Collibra Announces 2019 Excellence Awards Winners23.5.2019 15:00:00 CEST | Pressemelding
American Express, Deloitte, and Lloyds Banking Group recognized as leaders in harnessing data to drive digital transformation NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- Collibra, the leader in enterprise data governance and catalog software, today announced the winners of the 2019 Collibra Excellence Awards. Presented at the annual Data Citizens conference in New York, the awards honor teams and individuals driving innovative data strategy by collaborating with Collibra. “In today’s market, organizations that are able to maximize data have the power to transform entire industries,” said Felix Van de Maele, co-founder and CEO of Collibra. “We’re proud to honor the recipients of the Collibra Excellence Awards, a cutting-edge group at the forefront of data-driven innovation.” The 2019 Collibra Excellence Award Winners: American Express — Distinguished Data Program of the Year American Express was recognized for its data governance transformation, which began as a compliance initiative and
XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa23.5.2019 14:20:00 CEST | Pressemelding
AUSTIN, Texas, May 23, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced plans to advance its dermatology program for its true human antibody bermekimab with the launch of a randomized, double-blind, placebo controlled, Phase 2b clinical study in patients with moderate to severe Hidradenitis Suppurativa (HS). This Phase 2b study will evaluate safety and efficacy of bermekimab at different subcutaneous doses compared with placebo. The study will further evaluate efficacy of bermekimab in HS and guide dosing strategies for the anticipated Phase 3 registration study. The Company expects the first patient to be enrolled during the third quarter of 2019. The Phase 2b study follows two previous successful clinical studies of bermekimab to treat HS. XBiotech recently evaluated bermekimab in a phase 2 study involving two groups of patients with HS: those who had no prior treatment with biologics; and those who had failed the only approved biological therapy to treat HS. The study, whi
LGC CAPITAL Announces Results of Annual Meeting, Appointment of New Chairman and Approval of Name Change to Elixxer Ltd.23.5.2019 14:00:00 CEST | Pressemelding
MONTRÉAL, May 23, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) ("LGC" or the “Corporation”) is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held yesterday in Montreal, Quebec. At the Meeting, all five of the nominees listed in the Corporation’s management information circular dated April 17, 2019 were elected as directors, all with a vote of more than 92% of the shares voted in their favour. Accordingly, the directors of LGC for the ensuing year are Mohammed Ghafari, Mazen Haddad, Rafi Hazan, David Lenigas and Ferras Zalt. At the Meeting, shareholders adopted a special resolution approving a change in the name of the Corporation to “Elixxer Ltd.” or such other name as the Corporation’s directors may determine. The special resolution was supported by 98.94% of the votes cast at the Meeting. The Corporation intends to proceed with the name change as expeditiously as possible. Shareholders also adopted: a special
Merus Announces 2019 Annual General Meeting of Shareholders23.5.2019 14:00:00 CEST | Pressemelding
UTRECHT, The Netherlands, May 23, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the 2019 Annual General Meeting of Shareholders will be held on June 12, 2019 at 1:00 pm (CEST) at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands). All relevant documents and information for the meeting, including the notice and agenda, are available in the 'Investor Relations' section of Merus’ website (www.merus.nl) under “Financial Information”. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clin